KYMERA THERAPEUTICS INC's ticker is KYMR and the CUSIP is 501575104. A total of 136 filers reported holding KYMERA THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $391,782 | +1284.3% | 13,125 | +1764.3% | 0.01% | +600.0% |
Q1 2024 | $28,301 | -59.6% | 704 | -74.4% | 0.00% | 0.0% |
Q4 2023 | $70,092 | -24.2% | 2,753 | -58.6% | 0.00% | -66.7% |
Q3 2023 | $92,463 | +38.7% | 6,652 | +129.5% | 0.00% | +50.0% |
Q2 2023 | $66,648 | +128069.2% | 2,899 | +65.4% | 0.00% | 0.0% |
Q1 2023 | $52 | -61.5% | 1,753 | -67.5% | 0.00% | -66.7% |
Q4 2022 | $135 | -100.0% | 5,399 | -71.0% | 0.01% | -14.3% |
Q3 2022 | $405,000 | +78.4% | 18,622 | +61.5% | 0.01% | +40.0% |
Q2 2022 | $227,000 | +69.4% | 11,529 | +264.2% | 0.01% | +400.0% |
Q1 2022 | $134,000 | -54.3% | 3,166 | -31.4% | 0.00% | -80.0% |
Q4 2021 | $293,000 | +34.4% | 4,616 | +24.6% | 0.01% | -16.7% |
Q3 2021 | $218,000 | +162.7% | 3,706 | +115.5% | 0.01% | +200.0% |
Q2 2021 | $83,000 | +43.1% | 1,720 | +15.9% | 0.00% | +100.0% |
Q1 2021 | $58,000 | +23.4% | 1,484 | +97.9% | 0.00% | 0.0% |
Q4 2020 | $47,000 | +51.6% | 750 | -22.7% | 0.00% | – |
Q3 2020 | $31,000 | – | 970 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Life Science Advisors, LLC | 5,984,736 | $149,379,011 | 17.99% |
Aquilo Capital Management, LLC | 629,411 | $15,710,099 | 5.90% |
BVF INC/IL | 4,692,604 | $117,127,396 | 4.94% |
Artal Group S.A. | 2,000,000 | $49,920 | 2.79% |
Redmile Group, LLC | 2,673,837 | $66,738,972 | 2.73% |
Avoro Capital Advisors LLC | 3,850,000 | $96,096,000 | 1.44% |
Deer Management Co. LLC | 615,895 | $15,372,739 | 1.42% |
AtonRa Partners | 27,125 | $677,040 | 0.86% |
Rock Springs Capital Management LP | 1,227,779 | $30,645,364 | 0.74% |
EcoR1 Capital, LLC | 796,093 | $19,870,481 | 0.60% |